You are here

Roche Ends Development of Several Drugs

Among them, lampalizumab had fared poorly in phase 3 tests

In an update on pharmaceutical pipeline projects tucked inside its financial results, FierceBiotech reports, Swiss drugmaker Roche announced that it was pulling the plug on several early- and late-stage candidates.

The casualties:

  • Lampalizumab (RG7417), a phase 3 drug that last fall failed two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy due to age-related macular degeneration (AMD) and secondary to AMD. At one point, some analysts had predicted the drug could reach $2 billion in annual sales.
  • RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma that was in phase 1 testing.
  • RG6047, which was being tested in phase 1 for metastatic estrogen receptor-positive, HER2-negative breast cancer.
  • RG7203, a small-molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.

Source: FierceBiotech; February 1, 2018.

Recent Headlines

Scenesse is new treatment for people with rare, painful light sensitivity disease
Humira, Rituxan top list of drugs that added $5.1 billion to nation's health care bill
Lower court rulings cleared the way for generic versions of the MS drug
Maryland man wins lawsuit that alleges that the company's antipsychotic caused his gynecomastia
Antidepressants, ADHD meds are also used to self-poison
Study lists steps that could save close to $300 billion a year
While many victims used THC, the cause remains elusive
Descovy joins Truvada, another Gilead product, in the HIV prophylaxis market
Data show PTC Therapeutics drug preserves lung function